Skip to content

Study · Observational study · n = 645 · 1997

8 results

Therapeutic results with Cerebrolysin in the treatment of dementia.

Rainer M, Brunnbauer M, Dunky A, Ender F, Goldsteiner H, Holl O, Kotlan P, Paulitsch G, Reiner C, Stössl J, Zachhuber C, Mössler H

Wiener medizinische Wochenschrift (1946)1 Jan 1997Cited by 9 (Europe PMC)

PMID9408984 (opens in a new tab)PepBankPUB-09408984
Publisher pageAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In patients with dementia, memory improved in 62% after Cerebrolysin therapy (p < 0.001).

    In plain wordsIn patients with dementia, memory improved in 62% after Cerebrolysin therapy.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseMemory improvement
    Study

    n = 645

    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    30 ml daily · infusion · 17.8 days on averageAs given in this study (human).

    Measurements

    Memory responders
    62%
    treated patients
    p value for memory improvement
    < 0.001 p value
    Cerebrolysin therapy, memory improvement before versus after therapy

    Source sentences

    Summary
    Cerebrolysin therapy led to a significant (p < 0.001) improvement in memory for 62% of the patients.
    3 context sentences
    Summary · context
    In the present study patients suffering from dementia were treated with an infusion therapy using the neurotrophic drug Cerebrolysin.
    Summary · context
    645 Patients were treated with 30 ml Cerebrolysin daily.
    Summary · context
    The average period of treatment was 17.8 days.
  2. 02HumanObservational studyEfficacy outcome

    In patients with dementia, concentration improved in 65% after Cerebrolysin therapy.

    In plain wordsIn patients with dementia, concentration improved in 65% after Cerebrolysin therapy.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseConcentration improvement
    Study

    n = 645

    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    30 ml daily · infusion · 17.8 days on averageAs given in this study (human).

    Measurements

    Concentration responders
    65%
    treated patients

    Source sentences

    Summary
    65% showed improvement in concentration, 50% in mood and fatigue, and 47% improved in vertigo.
    3 context sentences
    Summary · context
    In the present study patients suffering from dementia were treated with an infusion therapy using the neurotrophic drug Cerebrolysin.
    Summary · context
    645 Patients were treated with 30 ml Cerebrolysin daily.
    Summary · context
    The average period of treatment was 17.8 days.
  3. 03HumanObservational studyEfficacy outcome

    In patients with dementia, mood improved in 50% after Cerebrolysin therapy.

    In plain wordsIn patients with dementia, mood improved in 50% after Cerebrolysin therapy.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseMood improvement
    Study

    n = 645

    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    30 ml daily · infusion · 17.8 days on averageAs given in this study (human).

    Measurements

    Mood responders
    50%
    treated patients

    Source sentences

    Summary
    65% showed improvement in concentration, 50% in mood and fatigue, and 47% improved in vertigo.
    3 context sentences
    Summary · context
    In the present study patients suffering from dementia were treated with an infusion therapy using the neurotrophic drug Cerebrolysin.
    Summary · context
    645 Patients were treated with 30 ml Cerebrolysin daily.
    Summary · context
    The average period of treatment was 17.8 days.
  4. 04HumanObservational studyEfficacy outcome

    In patients with dementia, fatigue improved in 50% after Cerebrolysin therapy.

    In plain wordsIn patients with dementia, fatigue improved in 50% after Cerebrolysin therapy.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseFatigue improvement
    Study

    n = 645

    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    30 ml daily · infusion · 17.8 days on averageAs given in this study (human).

    Measurements

    Fatigue responders
    50%
    treated patients

    Source sentences

    Summary
    65% showed improvement in concentration, 50% in mood and fatigue, and 47% improved in vertigo.
    3 context sentences
    Summary · context
    In the present study patients suffering from dementia were treated with an infusion therapy using the neurotrophic drug Cerebrolysin.
    Summary · context
    645 Patients were treated with 30 ml Cerebrolysin daily.
    Summary · context
    The average period of treatment was 17.8 days.
  5. 05HumanObservational studyEfficacy outcome

    In patients with dementia, vertigo improved in 47% after Cerebrolysin therapy.

    In plain wordsIn patients with dementia, vertigo improved in 47% after Cerebrolysin therapy.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseVertigo improvement
    Study

    n = 645

    Outcome group
    Overall treatment effect · Nervous system and cognition
    Studied dose
    30 ml daily · infusion · 17.8 days on averageAs given in this study (human).

    Measurements

    Vertigo responders
    47%
    treated patients

    Source sentences

    Summary
    65% showed improvement in concentration, 50% in mood and fatigue, and 47% improved in vertigo.
    3 context sentences
    Summary · context
    In the present study patients suffering from dementia were treated with an infusion therapy using the neurotrophic drug Cerebrolysin.
    Summary · context
    645 Patients were treated with 30 ml Cerebrolysin daily.
    Summary · context
    The average period of treatment was 17.8 days.
  6. 06HumanObservational studyEfficacy outcome

    In patients with dementia, Clinical Global Impression improved in approximately 80% after Cerebrolysin therapy.

    In plain wordsIn patients with dementia, overall clinical status improved in approximately 80% after Cerebrolysin therapy.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseClinical Global Impression improvement
    Study

    n = 645

    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    30 ml daily · infusion · 17.8 days on averageAs given in this study (human).

    Measurements

    CGI responders
    ≈ 80%
    treated patients

    Source sentences

    Summary
    An improvement in the Clinical Global impression was observed in approximately 80% of the patients.
    3 context sentences
    Summary · context
    In the present study patients suffering from dementia were treated with an infusion therapy using the neurotrophic drug Cerebrolysin.
    Summary · context
    645 Patients were treated with 30 ml Cerebrolysin daily.
    Summary · context
    The average period of treatment was 17.8 days.
  7. 07HumanObservational studySafety outcome

    In patients with dementia, the study reported good tolerance of Cerebrolysin without event counts.

    In plain wordsIn patients with dementia, the study reported good tolerance of Cerebrolysin.

    Peptide
    Cerebrolysin
    Outcome
    Not applicableTolerance
    Study

    n = 645

    Outcome group
    Adverse events · Whole body
    Studied dose
    30 ml daily · infusion · 17.8 days on averageAs given in this study (human).

    Source sentences

    Summary
    The unusual good tolerance of Cerebrolysin was especially noteworthy.
    3 context sentences
    Summary · context
    In the present study patients suffering from dementia were treated with an infusion therapy using the neurotrophic drug Cerebrolysin.
    Summary · context
    645 Patients were treated with 30 ml Cerebrolysin daily.
    Summary · context
    The average period of treatment was 17.8 days.
  8. 08HumanObservational studyEfficacy outcome

    After Cerebrolysin therapy, younger, less afflicted dementia patients showed greater symptom improvement than older, more seriously ill patients.

    In plain wordsAfter Cerebrolysin therapy, younger, less affected dementia patients improved more than older, more seriously ill patients.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseSymptom improvement by age and severity
    Study

    n: not reported in source

    Comparator
    Older, more seriously ill patients
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    30 ml daily · infusion · 17.8 days on averageAs given in this study (human).

    Measurements

    Symptom improvement p value
    < 0.05 p value
    Younger, less afflicted patients versus older, more seriously ill patients after Cerebrolysin therapy

    Source sentences

    Summary
    The improvement of symptoms was significantly larger (p < 0.05) in younger, less afflicted patients than in the older, more seriously ill patients.
    3 context sentences
    Summary · context
    In the present study patients suffering from dementia were treated with an infusion therapy using the neurotrophic drug Cerebrolysin.
    Summary · context
    645 Patients were treated with 30 ml Cerebrolysin daily.
    Summary · context
    The average period of treatment was 17.8 days.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.